<p><em>Long noncoding RNA H19</em> is a critical oncogenic driver and contributes to epithelial-mesenchymal transition in papillary thyroid carcinoma</p>

Abstract

BackgroundGrowing evidence has indicated that the long noncoding RNA H19 (lncRNA H19), frequently deregulated in almost all tumor types tested, acted as a pivotal contributor to both cancer initiation and progression. However, the role of lncRNA H19 in human papillary thyroid carcinoma (PTC) remains controversial. The aim of the study was to investigate the expression and potential function of lncRNA H19 in human PTC.Patients and methodsThe lncRNA H19 level was determined by quantitative real-time (RT)-PCR analyses in 58 PTC tissue samples and their paired paracancerous tissue samples. RNA interference, RT-PCR analysis, and Western blot assay were used to determine the impact of lncRNA H19 on epithelial-mesenchymal transition (EMT) markers in human PTC cells. The migratory and invasive capacities of PTC cells were determined by wound-healing and transwell migration and invasion assays.ResultslncRNA H19 expression was 2.417-fold higher in PTC tissues than their paired paracancerous tissue (95% CI: 1.898–2.935, P<0.0001). Higher level of lncRNA H19 was correlated to elevated expression of Vimentin, ZEB2, Twist, and Snail2. Inhibition of lncRNA H19 resulted in upregulation of E-cadherin and downregulation of Vimentin both at mRNA and protein levels. Conversely, enforced expression of the exogenous lncRNA H19 led to E-cadherin mRNA and protein downregulation and relative upregulation of Vimentin. Moreover, wound-healing and transwell migration and invasion assays showed that lncRNA H19 could promote the migratory and invasive abilities of PTC cells.ConclusionThe level of lncRNA H19 was significantly higher in PTC tissues than paired paracancerous tissue or normal tissues. Overexpression of lncRNA H19 was correlated with higher tumor burden of PTC. It also contributes to EMT process, as well as promotes migration and invasion of PTC cells.

Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis

“…H19 is also shown to be overexpressed in gastric cancer tissues, with increased expression of H19 relating to advanced pathological tumor stage and pathological tumor node metastasis stage [23]. In PTC tissues, H19 was significantly higher than paired paracancerous tissue or normal tissues, and overexpression of H19 was correlated with higher tumor burden of PTCs [18]. Li et al also found that H19 is highly expressed in papillary thyroid cancer stem cells (PTCSCs) and PTC tissue specimens, which is correlated with poor overall survival [24].…”

“…Liang et al reported that H19 was overexpressed in papillary thyroid carcinoma (PTC), and H19 overexpression contributes to epithelial-mesenchymal transition (EMT) [18]. However, Wang et al reported that H19 overexpression inhibited invasion and EMT in PTC cells [19], and Lan et al reported that H19 downregulation contributes to proliferation and migration in PTC cells [20].…”

<p>LncRNA LINC00665 Promotes Prostate Cancer Progression via miR-1224-5p/SND1 Axis</p>

“…9 LncRNA H19 overexpression promotes epithelial-mesenchymal transition of papillary thyroid cancer. 10 Aberrant downregulation of lncRNA STXBP5-AS1 in gastric cancer leads to accelerated growth and enhanced metastasis of tumor cells through activation of PI3K/AKT signal. 11 Due to their important roles, several lncRNAs may be effective biomarkers for diagnosis or prognosis in cancer.…”

lncRNA SNHG7 affects malignant tumor behaviors through downregulation of EZH2 in uveal melanoma cell lines

“…For example, ZFAS1 plays a tumor-suppressor role in breast cancer; however, it acts as an oncogene in non-small cell lung, colorectal, gastric, liver, ovarian and bladder cancer (39). Furthermore, the lncRNA, H19 has also been reported to have either anti-cancer or carcinogenic effects in different types of tumor (40,41). As research progresses, the role of SNHG7 in different types of tumor may gradually be confirmed.…”